Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-Blind, Adaptive, Active Comparator-Controlled, Dose-Ranging, Multicenter, Safety, Tolerability, and Immunogenicity Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine in Adults 18 Years of Age and Older

NCT07291635 is registered in ClinicalTrials.gov with Aramis Biotechnologies Inc. as lead sponsor.

NCT NCT07291635
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07291635 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-Blind, Adaptive, Active Comparator-Controlled, Dose-Ranging, Multicenter, Safety, Tolerability, and Immunogenicity Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine in Adults 18 Years of Age and Older
Lead sponsor
Aramis Biotechnologies Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 25, 2026
Completion date
December 31, 2026
Enrollment
728 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

influenza